Clinical Trial Update: Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin (E7389) in hormone-refractory prostate cancer has completed. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: Eisai Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-05-15